Janux Therapeutics

Yahoo Finance • 14 days ago

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

SAN DIEGO, April 01, 2026--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development c... Full story

Yahoo Finance • 2 months ago

Lowest Quant ranked small-cap stocks with positive EPS surprises

[Wall street sign on manhattan] franckreporter/iStock via Getty Images With the Q4 earnings season almost coming to an end, below is a list of small-cap stocks with positive quarterly EPS surprises ranked according to their lowest Seeking... Full story

Yahoo Finance • 2 months ago

Where is Janux Therapeutics (JANX) Headed According to Analysts?

Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the best immunotherapy stocks to buy according to hedge funds. JonesTrading maintained a Buy rating on Janux Therapeutics, Inc. (NASDAQ:JANX) on January 23, setting a price target of $50.00.... Full story

Yahoo Finance • 2 months ago

Bristol Myers Squibb Expands RNA And Cell Therapy Pipeline As Valuation Lags

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Bristol-Myers Squibb (NYSE:BMY) is acquiring Orbital Therapeutics in a $1.5b deal to expand its... Full story

Yahoo Finance • 2 months ago

Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The fifth stock on our list of best biotech stocks is Janux Therapeutics, Inc. TheFly reported on January 20 that Clear Street downgraded JANX to Hold from Bu... Full story

Yahoo Finance • 4 months ago

Janux Completes Phase 1a Dose-escalation In Phase 1 JANX008 Study; Expansion Cohorts To Commence

(RTTNews) - Janux Therapeutics, Inc. (JANX), a clinical-stage biopharmaceutical company, provided an update that the Phase 1a dose-escalation portion of the ongoing Phase 1 study evaluating JANX008 across multiple solid tumour indications... Full story

Yahoo Finance • 4 months ago

Here are the most and least likely M&A targets in biotech, according to Truist

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] French biotech (ABVX [https://seekingalpha.com/symbol/ABVX]) has emerged as the most likely acquisition target among biotechs in 2026, significantly o... Full story

Yahoo Finance • 4 months ago

Do JANX007’s Interim Results Put Janux Therapeutics’ (JANX) TRACTr Platform Competitiveness to the Test?

In early December 2025, Janux Therapeutics reported updated interim Phase 1 data for JANX007 in metastatic castration-resistant prostate cancer, showing anti-tumor activity with partial responses in 30% of evaluable patients and radiograph... Full story

Yahoo Finance • 4 months ago

Stocks making the biggest moves midday: Maplebear, Boeing, Credo Technology, XPO, MongoDB & more

Check out the companies making the biggest moves midday: Maplebear — The parent company of Instacart fell nearly 4% after Amazon said it's testing "ultra-fast" delivery of groceries in Seattle and Philadelphia. These deliveries take about... Full story

Yahoo Finance • 4 months ago

Stocks making the biggest moves premarket: MongoDB, Strategy, Signet Jewelers, Credo and more

Check out the companies making the biggest moves in premarket trading: MongoDB — Shares of the developer data platform soared 24% following strong third-quarter results. Adjusted earnings were $1.32 per share on revenue of $628 million, co... Full story

Yahoo Finance • 4 months ago

Biggest stock movers Tuesday: CRDO, MDB, and more

[Financial asset invest analysis with volume and candle stick chart] TERADAT SANTIVIVUT Stock futures were slightly up in the premarket hours of Tuesday amid a Bitcoin price decline and rising anticipation for a Federal Reserve interest r... Full story

Yahoo Finance • 4 months ago

Janux reports positive phase 1 results for JANX007 in mCRPC; stock down

[Close-Up Shot of Scientists Hands typing Data in Laptop in Laboratory] Tom Werner Janux Therapeutics (JANX [https://seekingalpha.com/symbol/JANX]) on late Monday reported [https://seekingalpha.com/pr/20324271-janux-announces-encouraging-... Full story

Yahoo Finance • 7 months ago

Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT

Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best up and coming stocks with huge upside potential. On September 10, Truist initiated coverage of Janux Therapeutics with a Buy rating and $100 price target. Truist believes that the co... Full story

Yahoo Finance • 7 months ago

Janux is a new Buy at Truist ahead of catalyst rich H2

[Usa ready for a stock market crash] franckreporter Truist Securities launched its coverage of Janux Therapeutics (NASDAQ:JANX [https://seekingalpha.com/symbol/JANX]) with a Buy recommendation and a $100 target on Wednesday, citing a cata... Full story

Yahoo Finance • 8 months ago

Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration

Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best small cap stocks with biggest upside potential. On August 5, Janux Therapeutics announced a clinical milestone in its collaboration with Merck & Co. Inc. (NYSE:MRK), with the first p... Full story

Yahoo Finance • 8 months ago

Janux Therapeutics stock hits 52-week low at 22.25 USD

Janux Therapeutics Inc. reached a new 52-week low, with its stock price falling to 22.25 USD. This recent dip underscores a challenging year for the biotechnology company, which has seen its stock value decline by 37.03% over the past 12 m... Full story

Yahoo Finance • 8 months ago

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the se... Full story

Yahoo Finance • 8 months ago

The Math Shows SCHA Can Go To $31

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 8 months ago

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux SAN DIEGO, August 05, 2025--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical compa... Full story

Yahoo Finance • 10 months ago

Janux Therapeutics reports annual meeting results

On June 11, 2025, Janux Therapeutics, Inc., a biotechnology company currently valued at $1.48 billion, conducted its 2025 Annual Meeting of Stockholders. The meeting occurred amid challenging market conditions, with the stock down over 58%... Full story